http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102396303-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2513-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-84 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-3616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0676 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 |
| filingDate | 2017-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102396303-B1 |
| titleOfInvention | Compositions and methods for reprogramming adult cells using a platelet-rich fraction of blood containing platelet-like cells |
| abstract | The described invention provides a method of functionally reprogramming an adult cell into an immature cell type expressing one or more embryonic biomarkers. Reprogramming involves contacting adult cells with a platelet-rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, expressing human beta-cell specific transcription factors, and producing insulin-producing functionally equivalent human pancreatic beta-cells. Generating a cell population is accomplished by expanding immature cell types in vitro under culture conditions. Without wishing to be bound by theory, platelet-like cells and their released mitochondria represent immune resistance-related markers that may modulate the function and differentiation of immune cells. The described invention further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population derived from a functionally reprogrammed adult cell, wherein the insulin-producing cell population is human beta-cell specific It expresses transcription factors and is functionally equivalent to human pancreatic beta-cells. |
| priorityDate | 2016-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 284.